Correlation analysis of FPGS rs10760502G>a polymorphism with prognosis and MTX-related toxicity in pediatric B-cell acute lymphoblastic leukemia.
10.7534/j.issn.1009-2137.2014.02.006
- Author:
Shu-Guang LIU
1
,
2
,
3
,
4
;
Chao GAO
1
;
Zhi-Gang LI
1
;
Wei-Jing LI
1
;
Lei CUI
1
;
Xiao-Xi ZHAO
1
;
Hu-Yong ZHENG
1
;
Min-Yuan WU
1
;
Rui-Dong ZHANG
1
;
Author Information
1. Hematology Oncology Center, Beijing Key Laboratory of Pediatric Hematology and Oncology
2. Key Laboratory of Major Diseases in Children, Ministry of Education
3. National Key Discipline of Pediatrics
4. Beijing Children's Hospital, Capital Medical University, Beijing 100045, China.
- Publication Type:Journal Article
- MeSH:
Adolescent;
Child;
Child, Preschool;
Female;
Genotype;
Humans;
Infant;
Leukemia, B-Cell;
diagnosis;
drug therapy;
genetics;
Male;
Methotrexate;
adverse effects;
Peptide Synthases;
genetics;
Polymorphism, Genetic;
Precursor Cell Lymphoblastic Leukemia-Lymphoma;
genetics;
Prognosis
- From:
Journal of Experimental Hematology
2014;22(2):291-297
- CountryChina
- Language:Chinese
-
Abstract:
This study was aimed to explore the relation between folylpolyglutamate synthetase (FPGS) rs10760502 polymorphism and prognosis and methotrexate (MTX)-related toxicities in pediatric B-cell acute lymphoblastic leukemia (B-ALL). Sequenom MassARRAY was used to genotype rs10760502. The χ(2) test, Kaplan-Meier method and Cox regression models were used to analyze the data. The results indicated that A allele carriers (GA+AA) had poor relapse free survival (RFS, log-rank: P = 0.004) and event free survival (EFS, log-rank: P = 0.022) compared with the GG genotype carriers. Multivariate Cox-regression analysis results showed that A allele is an independent prognosis factor for poor RFS [hazard ratio (HR), 20.173; 95% CI, 2.535-160.545; P = 0.005] and EFS (HR, 8.133; 95% CI, 1.718-38.512; P = 0.008). No relationship was found between any MTX toxicity and rs10760502 polymorphism. It is concluded that FPGS rs10760502G>A polymorphism may affect the treatment outcome of B-ALL patients.
